Complete the information below to be removed from the email communications list of GlaxoSmithKline Inc.
BEXSERO multicomponent meningococcal B vaccine (recombinant, adsorbed) is a vaccine for the prevention of meningococcal disease caused by Neisseria meningitidis group B bacteria in individuals from 2 months through 25 years of age. BEXSERO is not expected to protect against all circulating meningococcal serogroup B strains and does not offer protection against strains A, C, Y, and W-135. As with any vaccine, BEXSERO may not fully protect all of those who are vaccinated. BEXSERO does not treat or reduce the consequences of meningococcal disease, including meningitis, sepsis, and death. The very common side effects (may affect more than 1 in 10 people) after vaccination with BEXSERO (reported in all age groups) were pain/tenderness at the injection site, redness at the injection site, swelling of the skin at the injection site, and hardness of the skin at the injection site. In infants and children (up to 10 years of age), fever can occur more frequently when BEXSERO is given at the same time as routine infant vaccines. Allergic reactions may also occur. Ask your healthcare professional if BEXSERO is right for your child. Full product information can be found at http://gsk.ca/bexsero/en. To report an adverse event, please call 1-800-387-7374.
For information about how GSK uses, shares, and protects personal information, including information collected online, please read GSK's Privacy Statement.
Please note: This site does not provide medical advice. The contents of this site are for information purposes only and are not in any way intended to replace or substitute the advice of your healthcare professional. Your healthcare professional is the best source of information regarding your health. This digital channel is not intended as a means for reporting an adverse event (side effect) or complaint for any GlaxoSmithKline product. To report an adverse event or product complaint, please call 1-800-387-7374. This site is intended for use by Canadian residents only.